ALZA

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Retrieved on: 
Tuesday, February 20, 2024
ALZA, Mallinckrodt, Schering-Plough, Gedatolisib, Progeria, Marketing, Strategic planning, CELC, Organization, Fostamatinib, Pharmaceutical industry

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.

Key Points: 
  • MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.
  • Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.
  • Prior to Eiger, he was Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals where he built and led the commercial organization and launched Tavalisse® (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia.
  • “I am excited to join Celcuity and work alongside driven, collaborative colleagues during this pivotal time for the company,” said Eldon Mayer.

RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS

Retrieved on: 
Monday, August 28, 2023
Morgan Stanley, Maimonides Medical Center, IPO, IOMA, ALZA, Pediatrics, Biochemistry, Physician, Columbia University Vagelos College of Physicians and Surgeons, OTCQB, Brandeis University, Pediatric Research, Research, RNA, Associate, Professor, Columbia, Supergene, Surgeon, Steroid, Pharmaceutical industry, Medical device, SUNY

PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.

Key Points: 
  • PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.
  • As RetinalGeniX DNA-GPS™ seeks to evolve into a diagnostic and therapeutic company, it plans to use pharmacogenetic mapping and high-resolution imaging RetinalGeniX DNA-GPS to validate and guide the development of novel methods and therapeutic products.
  • “Dr.
  • We welcome the expertise that Fred brings to RetinalGeniX DNA-GPS to assist in the development of this new technology in healthcare,” said Dr. Larry Perich, Director of the DNA/GPS program at RetinalGeniX.

HACE Launches Inaugural ALZA Leadership Program; The program kicks off with inaugural cohort of leaders in April 2023

Retrieved on: 
Wednesday, April 5, 2023
JPMorgan Chase, Workforce, HACE, JPMC, Partnership, Employment, ALZA, Mentorship, Entrepreneurship, Montenegro, Corporation, AHL, Growth, National Leadership Grants for Libraries, Management, Payment card, Hispanic

CHICAGO, April 5, 2023 /PRNewswire-PRWeb/ -- The Hispanic Alliance for Career Enhancement (HACE), a Chicago-based national nonprofit dedicated to the employment, development, and advancement of current and aspiring Latino professionals, is proud to announce its new advanced leadership program, ALZA--a program designed to fuel the potential of Latino professionals. Sponsored by JPMorgan Chase, HACE is proud to welcome 15 JPMC leaders as part of the program's inaugural cohort of participants. The program provides guidance and support to help leaders obtain transformational leadership skills to help them achieve their professional goals, including executive roles. The effort will provide the inaugural cohort of senior leaders with personalized sessions and coaching led by subject matter experts.

Key Points: 
  • Sponsored by JPMorgan Chase, HACE is proud to welcome 15 JPMC leaders as part of the program's inaugural cohort of participants.
  • The program provides guidance and support to help leaders obtain transformational leadership skills to help them achieve their professional goals, including executive roles.
  • The effort will provide the inaugural cohort of senior leaders with personalized sessions and coaching led by subject matter experts.
  • The ALZA program, which kicks off this month and ends in November, uses the Insights©️ Leadership model as its foundation.

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Thursday, August 12, 2021
Forward-looking statement, PD-1, U.S. Securities and Exchange Commission, Clinical trial, Operation, Amgen, Human resources, American Society of Clinical Oncology, Research, Leadership, G&A, Immunotherapy, Safety, Industry, ASCO, Administration, GlaxoSmithKline, Research and development, CEA, Therapy, IND, Myelocyte, Annual report, ISAC, ALZA, Cancer, Translational medicine, Â, Kite Pharma, Society, Communication, Stanford University Medical Center, Trastuzumab, Conference, Breast, Ambit Biosciences, Poster, Gilead Sciences, Hematology, Program management, NASDAQ, Annual general meeting, Drug development, Immune stimulating antibody conjugate, Program, GLOBE, Antibody, Security (finance), Patient, Development, PD-L1, R, Vaccine, Pharmaceutical industry, Management, Cryptocurrency, Lease

REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.
  • The monotherapy dose-escalation portion of the trial is proceeding on plan, with a further data update expected in the second half of 2021.
  • Bolt also remains on track to initiate the monotherapy Phase 2 dose-expansion cohorts and the dose-escalation of BDC-1001 in combination with an anti-PD-1 antibody in the second half of 2021.
  • Lossfrom Operations Loss from operations was $23.8 million for the quarter ended June 30, 2021 compared to $11.1 million for the same quarter in 2020.

Expansion Therapeutics Expands Leadership Team with Two Key Appointments; Names World-Renowned Scientist Lynne E. Maquat, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, June 17, 2019
Health, Biotechnology, Pharmaceutical, Research, Science, Lynne E. Maquat, Johnson & Johnson, ALZA, California, Life sciences, Industries

Expansion also named world-renowned scientist and pioneer in RNA research, Prof. Lynne E. Maquat, Ph.D., of the University of Rochester, to its Scientific Advisory Board.

Key Points: 
  • Expansion also named world-renowned scientist and pioneer in RNA research, Prof. Lynne E. Maquat, Ph.D., of the University of Rochester, to its Scientific Advisory Board.
  • As Vice President of Chemistry Manufacturing and Controls (CMC) at Expansion, Dr. Shivanand will lead all CMC operations.
  • She has more than 20 years of experience in pharmaceutical product development including positions at ALZA Corporation and Johnson & Johnson.
  • Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.